JP2025510295A5 - - Google Patents
Info
- Publication number
- JP2025510295A5 JP2025510295A5 JP2024557207A JP2024557207A JP2025510295A5 JP 2025510295 A5 JP2025510295 A5 JP 2025510295A5 JP 2024557207 A JP2024557207 A JP 2024557207A JP 2024557207 A JP2024557207 A JP 2024557207A JP 2025510295 A5 JP2025510295 A5 JP 2025510295A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dmt
- meo
- social
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22000085 | 2022-03-27 | ||
| EP22000084.8 | 2022-03-27 | ||
| EP22000085.5 | 2022-03-27 | ||
| EP22000084 | 2022-03-27 | ||
| EP23154014.7 | 2023-01-30 | ||
| EP23153996 | 2023-01-30 | ||
| EP23154014 | 2023-01-30 | ||
| EP23153996.6 | 2023-01-30 | ||
| PCT/EP2023/057879 WO2023186832A1 (en) | 2022-03-27 | 2023-03-27 | 5-methoxy-n,n-dimethyltryptamine for the treatment of social/emotional withdrawal or detachment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510295A JP2025510295A (ja) | 2025-04-14 |
| JP2025510295A5 true JP2025510295A5 (enExample) | 2026-04-10 |
Family
ID=86007029
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557207A Pending JP2025510295A (ja) | 2022-03-27 | 2023-03-27 | 社会的／情動的引きこもりまたは離隔の処置のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
| JP2024557208A Pending JP2025510296A (ja) | 2022-03-27 | 2023-03-27 | 認知機能不全の処置のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
| JP2024557197A Pending JP2025510913A (ja) | 2022-03-27 | 2023-03-27 | 双極性障害の処置のための５－ＭｅＯ－ＤＭＴ |
| JP2024557761A Pending JP2025511084A (ja) | 2022-03-27 | 2023-03-27 | 睡眠障害の処置に使用するための５－ｍｅｏ－ｄｍｔ |
| JP2024557199A Pending JP2025510914A (ja) | 2022-03-27 | 2023-03-27 | 産後うつ病の治療 |
| JP2024557757A Pending JP2025512866A (ja) | 2022-03-27 | 2023-03-27 | 不安の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
| JP2024557206A Pending JP2025510294A (ja) | 2022-03-27 | 2023-03-27 | 精神運動遅滞の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557208A Pending JP2025510296A (ja) | 2022-03-27 | 2023-03-27 | 認知機能不全の処置のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
| JP2024557197A Pending JP2025510913A (ja) | 2022-03-27 | 2023-03-27 | 双極性障害の処置のための５－ＭｅＯ－ＤＭＴ |
| JP2024557761A Pending JP2025511084A (ja) | 2022-03-27 | 2023-03-27 | 睡眠障害の処置に使用するための５－ｍｅｏ－ｄｍｔ |
| JP2024557199A Pending JP2025510914A (ja) | 2022-03-27 | 2023-03-27 | 産後うつ病の治療 |
| JP2024557757A Pending JP2025512866A (ja) | 2022-03-27 | 2023-03-27 | 不安の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
| JP2024557206A Pending JP2025510294A (ja) | 2022-03-27 | 2023-03-27 | 精神運動遅滞の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
Country Status (9)
| Country | Link |
|---|---|
| US (10) | US20250213531A1 (enExample) |
| EP (8) | EP4499077A1 (enExample) |
| JP (7) | JP2025510295A (enExample) |
| KR (7) | KR20250005173A (enExample) |
| CN (5) | CN119546298A (enExample) |
| AU (7) | AU2023244447A1 (enExample) |
| CA (7) | CA3255709A1 (enExample) |
| IL (7) | IL315903A (enExample) |
| WO (9) | WO2023186837A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3753923A1 (en) | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| EP4155306A1 (en) | 2021-01-15 | 2023-03-29 | Beckley Psytech Limited | Neuroactive ergoline analogue |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| GB202306256D0 (en) * | 2023-04-27 | 2023-06-14 | Beckley Psytech Ltd | 5-Methoxy-N,N-Dimethyltryptamine Formulations |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2026078143A1 (en) | 2024-10-09 | 2026-04-16 | GH Research Ireland Limited | Combinations of 5-meo-dmt with antidepressants for treating depression |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200147038A1 (en) * | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| HUE069534T2 (hu) * | 2019-02-22 | 2025-03-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-dimetiltriptamint (5-MeO-DMT) tartalmazó készítmény mentális rendellenességek kezelésében történõ alkalmazásra |
| FI4349407T3 (fi) | 2019-02-22 | 2025-06-02 | Gh Res Ireland Limited | 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon |
| US12377112B2 (en) * | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| KR20260008838A (ko) * | 2020-02-18 | 2026-01-16 | 길가메쉬 파마슈티컬스, 인코포레이티드 | 기분 장애 치료에 사용되기 위한 특이적 트립타민 |
| WO2021216489A1 (en) * | 2020-04-20 | 2021-10-28 | Lobe Sciences Ltd. | Methods for treating mild traumatic brain injury, post traumatic stress disorder and mild traumatic brain injury |
| BR112022025306A2 (pt) * | 2020-06-12 | 2023-02-28 | Beckley Psytech Ltd | Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina |
| US11406619B2 (en) * | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US20240299353A1 (en) * | 2021-03-12 | 2024-09-12 | Alvarius Pharmaceuticals Ltd. | Compositions and methods for treating addictions comprising 5-meo-dmt |
| JP2024517738A (ja) * | 2021-04-26 | 2024-04-23 | アタイ セラピューティクス， インコーポレイテッド | 新規のｎ，ｎ－ジメチルトリプタミン組成物および方法 |
| US20240390301A1 (en) * | 2021-08-23 | 2024-11-28 | Gilgamesh Pharmaceuticals, Inc. | Combinations of peripheral 5-ht2a receptor antagonists and central 5-ht2a receptor agonists |
| EP4448488A2 (en) * | 2021-12-13 | 2024-10-23 | Beckley Psytech Limited | Benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
-
2023
- 2023-03-27 WO PCT/EP2023/057885 patent/WO2023186837A1/en not_active Ceased
- 2023-03-27 JP JP2024557207A patent/JP2025510295A/ja active Pending
- 2023-03-27 US US18/851,336 patent/US20250213531A1/en active Pending
- 2023-03-27 CA CA3255709A patent/CA3255709A1/en active Pending
- 2023-03-27 US US18/851,294 patent/US20250213528A1/en active Pending
- 2023-03-27 US US18/851,329 patent/US20250170099A1/en active Pending
- 2023-03-27 CN CN202380036934.8A patent/CN119546298A/zh active Pending
- 2023-03-27 WO PCT/EP2023/057828 patent/WO2023186798A1/en not_active Ceased
- 2023-03-27 CA CA3255640A patent/CA3255640A1/en active Pending
- 2023-03-27 EP EP23717037.8A patent/EP4499077A1/en not_active Withdrawn
- 2023-03-27 KR KR1020247035657A patent/KR20250005173A/ko active Pending
- 2023-03-27 AU AU2023244447A patent/AU2023244447A1/en active Pending
- 2023-03-27 IL IL315903A patent/IL315903A/en unknown
- 2023-03-27 CA CA3255652A patent/CA3255652A1/en active Pending
- 2023-03-27 IL IL315892A patent/IL315892A/en unknown
- 2023-03-27 IL IL315901A patent/IL315901A/en unknown
- 2023-03-27 CN CN202380042750.2A patent/CN119255799A/zh active Pending
- 2023-03-27 KR KR1020247035763A patent/KR20250005184A/ko active Pending
- 2023-03-27 WO PCT/EP2023/057879 patent/WO2023186832A1/en not_active Ceased
- 2023-03-27 IL IL315900A patent/IL315900A/en unknown
- 2023-03-27 WO PCT/EP2023/057878 patent/WO2023186831A1/en not_active Ceased
- 2023-03-27 CN CN202380042391.0A patent/CN119255798A/zh active Pending
- 2023-03-27 US US18/851,316 patent/US20250213530A1/en not_active Abandoned
- 2023-03-27 US US18/851,311 patent/US20250213529A1/en active Pending
- 2023-03-27 CN CN202380037532.XA patent/CN119278036A/zh active Pending
- 2023-03-27 EP EP23717038.6A patent/EP4499078A1/en active Pending
- 2023-03-27 AU AU2023246548A patent/AU2023246548A1/en active Pending
- 2023-03-27 EP EP23717413.1A patent/EP4499089A1/en active Pending
- 2023-03-27 US US18/851,349 patent/US20250213533A1/en active Pending
- 2023-03-27 EP EP23717044.4A patent/EP4499084A1/en active Pending
- 2023-03-27 EP EP23717045.1A patent/EP4499085A1/en active Pending
- 2023-03-27 JP JP2024557208A patent/JP2025510296A/ja active Pending
- 2023-03-27 US US18/851,301 patent/US20250235427A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057845 patent/WO2023186808A1/en not_active Ceased
- 2023-03-27 CA CA3255654A patent/CA3255654A1/en active Pending
- 2023-03-27 KR KR1020247035720A patent/KR20250005178A/ko active Pending
- 2023-03-27 JP JP2024557197A patent/JP2025510913A/ja active Pending
- 2023-03-27 JP JP2024557761A patent/JP2025511084A/ja active Pending
- 2023-03-27 CN CN202380035882.2A patent/CN119156212A/zh active Pending
- 2023-03-27 IL IL315904A patent/IL315904A/en unknown
- 2023-03-27 KR KR1020247035719A patent/KR20250005177A/ko active Pending
- 2023-03-27 US US18/851,362 patent/US20250213534A1/en active Pending
- 2023-03-27 KR KR1020247035707A patent/KR20250005175A/ko active Pending
- 2023-03-27 AU AU2023246773A patent/AU2023246773A1/en active Pending
- 2023-03-27 JP JP2024557199A patent/JP2025510914A/ja active Pending
- 2023-03-27 WO PCT/EP2023/057875 patent/WO2023186828A1/en not_active Ceased
- 2023-03-27 KR KR1020247035654A patent/KR20240167878A/ko active Pending
- 2023-03-27 AU AU2023242439A patent/AU2023242439A1/en active Pending
- 2023-03-27 CA CA3255338A patent/CA3255338A1/en active Pending
- 2023-03-27 EP EP23717041.0A patent/EP4499081A1/en not_active Withdrawn
- 2023-03-27 AU AU2023246681A patent/AU2023246681A1/en active Pending
- 2023-03-27 JP JP2024557757A patent/JP2025512866A/ja active Pending
- 2023-03-27 CA CA3255329A patent/CA3255329A1/en active Pending
- 2023-03-27 IL IL315905A patent/IL315905A/en unknown
- 2023-03-27 CA CA3255511A patent/CA3255511A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057874 patent/WO2023186827A1/en not_active Ceased
- 2023-03-27 AU AU2023244453A patent/AU2023244453A1/en active Pending
- 2023-03-27 EP EP23717032.9A patent/EP4499072A1/en active Pending
- 2023-03-27 EP EP23717034.5A patent/EP4499074A1/en active Pending
- 2023-03-27 JP JP2024557206A patent/JP2025510294A/ja active Pending
- 2023-03-27 AU AU2023244449A patent/AU2023244449A1/en active Pending
- 2023-03-27 IL IL315895A patent/IL315895A/en unknown
- 2023-03-27 KR KR1020247035759A patent/KR20250005182A/ko active Pending
- 2023-03-27 WO PCT/EP2023/057868 patent/WO2023186821A1/en not_active Ceased
- 2023-03-27 WO PCT/EP2023/057871 patent/WO2023186824A1/en not_active Ceased
- 2023-09-27 US US18/373,904 patent/US20240115549A1/en active Pending
- 2023-09-27 US US18/373,914 patent/US20240115550A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025510295A5 (enExample) | ||
| Cummings et al. | Alzheimer’s disease: novel targets and investigational drugs for disease modification | |
| JP2025510369A5 (enExample) | ||
| JP2025511084A5 (enExample) | ||
| JP2025510294A5 (enExample) | ||
| US6335021B1 (en) | Composition for controlling mood disorders in healthy individuals | |
| JP2025510913A5 (enExample) | ||
| JP2025510368A5 (enExample) | ||
| JP2025510916A5 (enExample) | ||
| Moldofsky et al. | A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy | |
| JP2025512831A5 (enExample) | ||
| JP2025510296A5 (enExample) | ||
| JP2025511081A5 (enExample) | ||
| EP3215148B1 (en) | Use of low dose of tetrahydrocannabinol for the treatment of cognitive decline in elderly patients | |
| JP2025510914A5 (enExample) | ||
| Hale et al. | Clomipramine, tryptophan and lithium in combination for resistant endogenous depression: seven case studies | |
| JP2022511194A5 (enExample) | ||
| JP2024546121A5 (enExample) | ||
| JP2025148449A5 (enExample) | ||
| JP2024536581A5 (enExample) | ||
| TW201320994A (zh) | 投藥療程 | |
| Herzberger et al. | Homeopathic treatment of infections of various origins: a prospective study | |
| JP2024531799A5 (enExample) | ||
| JP2012031141A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| Moore et al. | Trial of reserpine in treatment of schizophrenia |